ArticleNucleic acids research2024
CRISPR-Cas tools for simultaneous transcription & translation control in bacteria.
Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Engineered bacterial therapeutics from synthetic biology to clinical translation: A multi-database scientometric analysis, 2000-2026.Human vaccines & immunotherapeutics · 2026Review
- Transposon-based genome editing of industrial microorganisms: advances, challenges, and prospects.Synthetic and systems biotechnology · 2026Review
- A portable Cas6f-based system for multiplex translational repression in bacteria.Nature communications · 2026Article
- Programmable control of bacterial operons with a single Cas13 RNA effector.Nature biotechnology · 2026Article
- Programmable, multiplexed and orthogonal gene control in bacteria with attenuated Cas13d systems.Nature biotechnology · 2026Article
- Multi-layered metabolic remodeling ofMetabolic engineering communications · 2026Article
- CRISPR/Cas9-Mediated Metabolic Engineering of EndophyticACS omega · 2026Article
- Construction of a Tl-CRISPRi Genetic Circuit in Bacteria for Translation-Level Gene Knockdown.Methods in molecular biology (Clifton, N.J.) · 2026Article
- CRISPR-based Transcriptional Regulation: Technologies, Applications, and Future Directions.DNA · 2025Article
- Conditional guide RNA deactivation by mRNA and small molecule triggers in Saccharomyces cerevisiae.New biotechnology · 2025Article
- CRISPR/Cas13X-assisted programmable and multiplexed translation regulation for controlled biosynthesis.Nucleic acids research · 2025Article
- The rise and future of CRISPR-based approaches for high-throughput genomics.FEMS microbiology reviews · 2024Review
- Editing microbes to mitigate enteric methane emissions in livestock.World journal of microbiology & biotechnology · 2024Review
- CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics.Biodesign research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Robust control over gene translation at arbitrary mRNA targets is an outstanding challenge in microbial synthetic biology. The development of tools that can regulate translation will greatly expand our ability to precisely control genes across the genome. In Escherichia coli, most genes are contained in multi-gene operons, which are subject to polar effects where targeting one gene for repression leads to silencing of other genes in the same operon. These effects pose a challenge for independently regulating individual genes in multi-gene operons. Here, we use CRISPR-dCas13 to address this challenge. We find dCas13-mediated repression exhibits up to 6-fold lower polar effects compared to dCas9. We then show that we can selectively activate single genes in a synthetic multi-gene operon by coupling dCas9 transcriptional activation of an operon with dCas13 translational repression of individual genes within the operon. We also show that dCas13 and dCas9 can be multiplexed for improved biosynthesis of a medically-relevant human milk oligosaccharide. Taken together, our findings suggest that combining transcriptional and translational control can access effects that are difficult to achieve with either mode independently. These combined tools for gene regulation will expand our abilities to precisely engineer bacteria for biotechnology and perform systematic genetic screens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.